IDEXX Laboratories, Inc. $IDXX Shares Sold by Private Trust Co. NA

Private Trust Co. NA lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 191 shares of the company’s stock after selling 49 shares during the quarter. Private Trust Co. NA’s holdings in IDEXX Laboratories were worth $102,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Mutual of America Capital Management LLC increased its stake in IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 3,766.7% during the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after buying an additional 113 shares during the last quarter. Plato Investment Management Ltd increased its position in shares of IDEXX Laboratories by 37.1% in the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after acquiring an additional 835 shares during the period. Genesis Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $215,000. Finally, ORG Wealth Partners LLC purchased a new position in IDEXX Laboratories in the 2nd quarter worth $273,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $633.78 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The company has a 50 day moving average price of $638.91 and a 200-day moving average price of $554.07. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The firm has a market cap of $50.70 billion, a price-to-earnings ratio of 52.77, a price-to-earnings-growth ratio of 4.12 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business earned $2.44 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on IDXX. Piper Sandler reiterated a “neutral” rating and set a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Leerink Partners upped their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective for the company. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $656.50.

Insider Buying and Selling

In other news, EVP Sharon E. Underberg sold 5,450 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the completion of the sale, the chief executive officer directly owned 83,311 shares in the company, valued at $52,650,885.78. This represents a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 in the last ninety days. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.